High Court refuses application for special leave to appeal Full Court finding that extended release venlafaxine patent invalid

On Friday, Justices Gummow, Hayne and Keiffel refused an application for Special Leave to appeal to the High Court a decision of the Full Court of the Federal Court which found that Wyeth’s patent relating to a method of treatment using an extended release formulation of the anti-depressant venlafaxine was invalid for lack of fair basis on the specification as filed, and on the ground that that the claims were not fairly based on an earlier US priority document.

King & Wood Mallesons acted for Alphapharm in opposing the application for special leave.

 

Liked this post? Share it…EmailLinkedInFacebookGoogle+DiggTwitterReddit
Categories: